Immunome

Forecast & Rating17 analysts currently cover Immunome, with about 94.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $35.33, about 96.4% upside from the current price of $17.99. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 43.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Immunome closely still see room for the stock to rise. Data as of Oct 23, 2026; for reference only and not investment advice.